To reach the next value inflection
LicenseRx asset brief
Increased Therapeutic Effectiveness of PE-Based Immunotoxins
Probability of Success
16% · grade B · Medium data confidence
Model PoS 16% (grade B, medium data confidence). Strongest signals: IP position, Indication pull. Biggest drag: Competitive whitespace.
Data maturity (22%)
41
Early / Discovery; human data.
IP position (16%)
88
Issued/granted patent on record.
Modality feasibility (14%)
66
Biologic/antibody -- solid path but higher CMC burden.
Indication pull (14%)
82
Oncology -- active buyer appetite.
Competitive whitespace (12%)
60
Crowded oncology field.
Translational evidence (12%)
70
Public evidence mentions: human, murine, patient.
Licensing readiness (10%)
94
Listed as available for licensing; established tech-transfer office; 1 public source link(s).
Unlock the full strategic deep dive
Cost to the next milestone, decisive data, relevant articles, and the partner-ready development plan for this asset.
View Operator access See what's included →